title: "The Dengue Vaccine Is Here. It Doesn't Cover Everyone." date: "2026-05-05" excerpt: "Takeda's Qdenga is approved in 41 countries and has 7-year efficacy data. But with 61% efficacy and Dengvaxia exiting the market, bite prevention remains essential. Here's why." category: "vaccines" author: "Mosticare Editorial"

The Dengue Vaccine Is Finally Here. It Doesn't Cover Everyone.

By Mosticare Editorial | Published 2026-05-05

For most of the 20th century, dengue had no vaccine. The virus's four serotypes, its complex immune interactions, and the risk of antibody-dependent enhancement, a phenomenon where prior exposure to one serotype can actually worsen a second infection, made developing a safe, effective dengue vaccine one of the hardest problems in infectious disease science.

That problem has now been substantially solved. Takeda Pharmaceuticals' dengue vaccine, Qdenga (TAK-003), has been approved in 41 countries, endorsed by the WHO, and as of 2026 has seven years of Phase III follow-up data from the landmark TIDES trial showing sustained protection across all four dengue serotypes. This is a genuine scientific milestone, something to celebrate without qualification.

And yet the numbers contain a gap that matters enormously for how we think about dengue protection.

What Qdenga Actually Delivers

The TIDES trial is one of the most comprehensive vaccine efficacy studies in recent memory. More than 20,000 participants across eight countries, randomised two-to-one between vaccine and placebo, followed for seven years. The results, updated in 2025–26, confirm:

The hospitalisation figure is particularly important. Dengue kills through its severe presentations, haemorrhagic fever, dengue shock syndrome, rather than through the typical self-limiting febrile illness that most infected people experience. A vaccine that prevents 90% of hospitalisations is protecting people from the cases that matter most clinically.

Qdenga is currently approved in approximately 41 countries, holds WHO prequalification, and has approximately 18 million doses administered globally as of early 2026. For endemic regions, for travellers, and increasingly for residents of Europe's Mediterranean coast where dengue transmission is occurring locally, it represents a real, evidence-based option.

The Number Nobody Mentions: 38.8%

Vaccine efficacy of 61.2% means that, in a population of 100 fully vaccinated people exposed to dengue, approximately 39 will still get the disease.

This is not a failure of the vaccine, 61% efficacy against a four-serotype virus with complex immune dynamics is a genuinely difficult target to hit, and Qdenga hits it reliably. But it is a number that has real-world implications for how dengue prevention should be structured.

The WHO's own guidance on dengue vaccination explicitly recommends vaccination as part of an integrated prevention strategy, not as a standalone tool. The WHO position paper on dengue vaccines continues to emphasise that vaccination should be complemented by vector control, personal protection, and healthcare system readiness. The vaccine reduces the probability of infection. It does not eliminate exposure.

For a traveller spending two weeks in Thailand, a 61% reduction in dengue risk is substantial. For a child growing up in a dengue-endemic neighbourhood, experiencing multiple exposure events per year across a decade of childhood, the residual 39% risk over a lifetime of exposure becomes significant. Layered protection, vaccine plus physical prevention, is not just cautious thinking; it is what the clinical data recommends.

The Dengvaxia Exit Changes the Landscape

In parallel with Qdenga's success, Sanofi has announced the discontinuation of its dengue vaccine Dengvaxia by Q3 2026, citing "a lack of demand on the global market."

Dengvaxia's commercial failure has a specific cause. The vaccine was approved in 2016 and rolled out in the Philippines, where it was administered to nearly one million schoolchildren before a 2017 reanalysis of efficacy data revealed a troubling pattern: in individuals who had never previously been infected with dengue (seronegative), the vaccine appeared to increase the risk of severe dengue upon subsequent natural infection. The Filipino government suspended the programme, criminal charges were filed against Sanofi executives, and the vaccine's reputation never recovered.

The Dengvaxia episode had a chilling effect on dengue vaccine development broadly and made regulatory agencies significantly more cautious about approval pathways. It is one of the reasons Qdenga's TIDES trial was so large and so long: the field needed to demonstrate unambiguous safety in seronegative individuals before a successor product could achieve broad uptake. Qdenga has cleared that bar.

The withdrawal of Dengvaxia means the global dengue vaccine market is now effectively a monopoly, Qdenga is the only WHO-prequalified dengue vaccine remaining in active distribution. A third candidate, Butantan-DV (developed in Brazil and approved by ANVISA in November 2025), is currently restricted to the Brazilian market, where a pilot rollout is underway in three cities.

Vaccine market concentration is not inherently problematic, but it underlines the importance of not treating any single tool as sufficient.

What About Europe Specifically?

European dengue risk sits at an interesting intersection of vaccination access and transmission dynamics.

The EU has not included dengue vaccination in any national immunisation programme as of 2026. Qdenga is available through travel clinics and some specialist practices in EU countries where it has national authorisation, but it is not systematically offered. This means that the vast majority of European residents living in or travelling to dengue-risk areas are unvaccinated.

At the same time, locally acquired dengue is now an annual reality in parts of southern France, Spain, and Italy. In 2024, the EU recorded more than 300 autochthonous dengue cases, up from 71 in 2022. As Aedes albopictus expands into central and northern Europe, the catchment area for locally acquired cases is growing.

For Europeans, the practical calculus is straightforward:

Layered Defence: The Standard the Data Supports

The phrase "layered protection" gets used freely in public health communications, but it deserves unpacking. It does not mean using multiple imperfect tools to feel busy. It means recognising that different protective mechanisms operate through different pathways, and combining them produces a combined efficacy that no single tool achieves.

A vaccinated individual who also uses physical barriers, screens, nets, appropriate clothing during peak biting hours, reduces their exposure probability at two independent points: they are less likely to become infected if bitten (vaccine efficacy), and they are less likely to be bitten at all (physical protection). The mathematical combination of these effects, even when each individual element is imperfect, produces substantially better overall protection.

Qdenga is a landmark achievement. Dengue vaccine science has arrived. But the science also says that 39 out of 100 vaccinated people are not protected, that the vaccine market now has only one global player, and that transmission seasons in Europe are getting longer and geographically wider.

The answer to all three of those data points is the same: don't put everything on one tool.

Sources: Qdenga (TAK-003) 7-year Phase III data, Clinical Trials Arena | WHO Dengue vaccine prequalification | WHO Dengue fact sheet | MedicalXpress — Dengue vaccine 80.5% efficacy at 5 years | ECDC Dengue surveillance

Mosticare produces structural mosquito-barrier solutions for residential, travel, and institutional markets across Europe.